Tackling cisplatin resistance in ovarian cancer: what can we do?

Perego, Paola

doi:10.20517/cdr.2021.59

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 493 BAX mutations are found in ~21% of human hematopoietic malignancies such as ALL. 494 Reduced BAX expression is a major factor in cisplatin resistance of ovarian cancer cells, 495 5-FU resistance of CRC cells, 496 and zoledronate resistance of lung cancer cells. 497 The decreased BAX/BCL-2 ratio can be induced by BAX abnormalities, which affects the temozolomide-induced resistance in U87MG cells and paclitaxel-resistant breast cancer cells.…”

Section: Classification Of Tumor Biomarkersmentioning

confidence: 99%

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Zhou,

Tao,

Qiu

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.

show abstract

Section: Classification Of Tumor Biomarkersmentioning

confidence: 99%

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Zhou,

Tao,

Qiu

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…The therapy of testicular germ cell cancer with cisplatin shows curing rates of 95%. However, resistant forms of this and other cancers such as ovarian cancers treated with platinum complexes pose a considerable clinical problem [ 35 , 36 ] . Cisplatin resistance is mediated by MYB proteins.…”

Section: Myb Proteins and Cancer Drug Resistancementioning

confidence: 99%

Emerging role of MYB transcription factors in cancer drug resistance

Biersack,

Höpfner

2024

Cancer Drug Resist

View full text Add to dashboard Cite

Decades ago, the viral myeloblastosis oncogene v -myb was identified as a gene responsible for the development of avian leukemia. However, the relevance of MYB proteins for human cancer diseases, in particular for solid tumors, remained basically unrecognized for a very long time. The human family of MYB transcription factors comprises MYB (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed in several cancers and are associated with cancer progression and resistance to anticancer drugs. In addition to overexpression, the presence of activated MYB-fusion proteins as tumor drivers was described in certain cancers. The identification of anticancer drug resistance mediated by MYB proteins and their underlying mechanisms are of great importance in understanding failures of current therapies and establishing new and more efficient therapy regimens. In addition, new drug candidates targeting MYB transcription factor activity and signaling have emerged as a promising class of potential anticancer therapeutics that could tackle MYB-dependent drug-resistant cancers in a more selective way. This review describes the correlation of MYB transcription factors with the formation and persistence of cancer resistance to various approved and investigational anticancer drugs.

show abstract

Non-coding RNA and drug resistance in head and neck cancer

Zhang,

Peng,

Lin

et al. 2024

Cancer Drug Resist

View full text Add to dashboard Cite

Head and neck cancer (HNC) is ranked as the sixth most common malignant tumor, and the overall survival rate with current treatment options remains concerning, primarily due to drug resistance that develops following antitumor therapy. Recent studies indicate that non-coding RNAs play a crucial role in drug resistance among HNC patients. This article systematically reviews the current research landscape, explores novel targets and treatment strategies related to non-coding RNAs and HNC resistance, raises some unresolved issues, and discusses five promising research directions in this field: ferroptosis, nanomedicine, exosomes, proteolysis-targeting chimeras (PROTACs), and artificial intelligence. We hope that our work will contribute to advancing research on overcoming HNC resistance through the regulation of non-coding RNAs.

show abstract

Tackling cisplatin resistance in ovarian cancer: what can we do?

Cited by 3 publications

References 5 publications

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Emerging role of MYB transcription factors in cancer drug resistance

Non-coding RNA and drug resistance in head and neck cancer

Contact Info

Product

Resources

About